Innovation Pharmaceuticals Inc (IPIX)

[Brinjal]

The NRx PR announcing the results does not say:

1. It was a double-blind study.
2. It followed the 29-day protocol expected of such studies.

Moreover, the admission process goes something like, and I quote "Assignment to ZYESAMI in the trial was based on the specific medical team which admitted the patient to the intensive care unit (ICU)". Does this give you sufficient confidence that the admission process was unbiased? Could these be the reasons why FDA was skeptical?

Isn't this a lot different from how IPIX conducted its trial?

Is it time to bring out your "Phosp...", whatever you mentioned before, out of the quiver and regurgitate it?

https://www.nrxpharma.com/nrx-pharmaceuticals-announces-improved-survival-at-one-year-in-highly-comorbid-covid-19-patients-treated-with-zyesami-aviptadil/